The emergence of the largest drug class we've ever seen is intersecting with rapid advancements in AI. Thanks to @FastCompany for publishing our POV on why & how these dual trends may lead to an unprecedented rate of innovation in cardiometabolic treatment

RT @creativedlab: CDL is excited to announce a strategic collaboration with @Dandelion_AI4H, a product development platform for clinical A…

RT @creativedlab: "We are delighted to partner with CDL to get Dandelion’s de-identified data into the hands of new ventures that have the…

To read the full GLP-1 research study and download our latest whitepaper, follow this link: Fill out our contact form if you want to use this real-world data for your own research.

We aim to release this research on a rolling basis. Further applications in cardiology, immunology, neurology, liver disease, and more are soon to follow. Reach out if you'd like to use our multimodal data or these algo outputs for your own projects: (6/6)

2️⃣ The next frontier for pharma in obesity Tx is improving the quality of weight loss, so another partner is running their algo on our CTs to quantify muscle vs fat vs liver fat pre/post-GLP-1 initiation. These could be trial endpoints as combo GLP-1s get closer to phase 3 (4/6)

1️⃣Liver fat and MASH/MAFLD seem to be the next therapeutic area for incretins (ex: GLP-1s) to conquer, so one of our partners is running their algorithm on our GLP-1 library data (CT scans pre/post GLP-1 initiation) to quantify changes in liver fat (3/6)

Using our GLP-1 data library, which launched this week, we have three studies underway using multimodal clinical data and AI to examine GLP-1s' impact in the real world 👇(2/6)

RT @FierceHealthIT: Health tech startup @Dandelion_AI4H launches data library to advance insights into GLP-1 drugs

Health tech startup Dandelion Health launches data library to advance insights into GLP-1 drugs

🎯 The Dandelion GLP-1 data library is representative of the US patient population, so you can build precision medicine tools that match patients to the right treatment plans at the right time Read our press release to learn more: #GLP1 #RWD #RWE (8/8)